Streetleaf Illuminates Babcock Ranch, Bringing Solar-Powered Streetlights to The Hometown of Tomorrow, Further Broadening the Community's Sustainability Focus and Resilience
'At Babcock Ranch, our goal is to lead the way in sustainable development and key partners like Streetlfeaf, with their incredible expertise in solar street lighting, are an important part of making that possible,' said Syd Kitson, Chairman and CEO of Kitson & Partners, developer of Babcock Ranch. 'Streetleaf's innovative approach aligns perfectly with our commitment to building a community that sets new standards for sustainability, innovation and resilience.'
The partnership between Babcock Ranch and Streetleaf will roll out in four phases. The first phase began and was completed in the fall of 2024, and the other three are planned by the end of 2025. There are 110 Streetleaf streetlights currently installed and illuminating The PKWY at Babcock Ranch, an expansive collection of six interconnected public parks. These include Bluebird Park, Hillcrest Park,The Lagoon, Explorers Park, Bark Park and Palmetto Park. Streetleaf provides the installation, lighting, routine maintenance, and 24/7 monitoring. Each light also has the ability to attach security cameras for safety and banners for social purposes to each of the poles, all while still maintaining wind ratings.
'Babcock Ranch is known for its forward-thinking sustainability and resilience, and we are honored to be their streetlighting provider,' stated Liam Ryan, CEO of Streetleaf. 'This highlights the need to meet the demand for sustainable living solutions, and storm resilient infrastructure especially in Florida.'
Babcock Ranch is recognized as a Shine on Florida community. This is a statewide program hosted by Streetleaf to encourage local leaders and businesses to install Streetleaf's hurricane resilient streetlights for safety and light in advance of the upcoming hurricane season.
ABOUT STREETLEAF
Headquartered in Tampa, Florida, Streetleaf specializes in integrating modern, renewable technology into communities through one of the most essential yet often-overlooked features—streetlights. Since its founding in 2019, Streetleaf has installed over 10,000 lights across the country, from Florida to California, and is rapidly growing to meet the rising demand for resilient, sustainable solutions. Streetleaf uses high-quality, dependable and proprietary hardware, software, and service to partner with land developers, builders, municipalities, utilities, and HOAs to create safer, greener communities. A carbon-neutral certified company, Streetleaf is also Darksky approved, and has offset more than 4 million pounds of CO2 and counting. Learn more at www.streetleaf.com. To learn more about Shine On Florida visit www.streetleaf.com/shine-on-florida.
Attachments
Carson Quinn ZindseyMEDIA for Streetleaf 312.339.9779 [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
29 minutes ago
- Forbes
How The B Corp Community Is Adapting To Life In 2025
B Corp accreditation has long been seen as a benchmark for environmental and ethical business practices, but with all the economic and geo-political upheaval in recent years, is there still a place for it in the new world order? The chief executive of B Lab UK, Chris Turner, said that while some businesses may be tempted to roll back on issues like sustainability, B Corps have made clear commitments on issues like climate change. Turner added that there are now over 2,600 B Corps in the U.K., which is the largest and fastest-growing B Corp community in the world, in an interview. He said recently published data from B Lab UK's 2024 brand awareness survey revealed a high recognition across the U.K. The survey also found almost two-thirds (63%) of respondents saying they use the certifications to help them make decisions on which businesses to buy from or work for, up from 58% in 2023 and 56% in 2022. The survey also found nearly three-quarters (74%) of the public agree or strongly agree that consumers can impact environmental sustainability through their purchases. And around two-thirds (65%) felt the same about impacting social change. 'We also have more than 3,000 companies backing our Better Business Act campaign,' he added. 'Momentum in the U.K. is still very strong, which is clearly a positive sign.' Turner said B Corps can act as a 'counter-narrative' because they have a clear purpose and are likelier to stay the course, while others roll back on some initiatives. 'There are also some businesses out there who are still doing the same work, but not talking about it as much, or changing some of the language they use,' he told me. 'I don't necessarily think that's a bad thing,' he added. 'The most important thing is the work gets done and the positive impact gets delivered.' Turner said the B Corp movement has seen rapid growth in the last few years, with many brands telling a compelling story about why they are adopting business models with a purpose. 'At the same time, the story that's been playing out alongside that momentum is the need to raise the bar for purposeful business,' said Turner. 'The urgency of the challenges we face means our whole mission as a movement is about how B Corps can lead the way and show what businesses can, and should, be doing.' 'What's really exciting about where we are now as a movement is how those things are coming together. It willbe vital over the next couple of years, as all B Corps move on to B Lab's new standards and we bring new businesses into the movement, to continue going forward and making the progress needed.' Tribe Impact Capital's co-founder and chief impact officer, Amy Clarke, said that sustainability has always faced a certain degree of resistance and has previously had to pivot and adapt as circumstances change. Clarke added that it feels like sustainability is in another 'adaptation phase' at the moment, but one that she hopes will address the root of the world's challenges. 'This is only going to further help sustainability evolve into what it really should be about, which is the common good,' she told me. 'And what the B Corp standards have done is say 'we have this incredible program of assessment in place that has really helped us communicate to the broader world what businesses which trade in the currency of forces for change look like'.' 'This is fundamentally about who you are. It has turbo-charged our credibility and enabled us to attract new employees and clients, who have seen we have not bowed at the first sign of major trouble and, if anything, we have stood up even taller.' And the global B Corp impact manager at Intrepid Travel, Rochelle Turner, said the B Corp movement helps create a framework for businesses and identify opportunities to make improvements, in an interview. Turner added that it also gives businesses like Intrepid Travel the opportunity to be part of a wider community, highlight how you can be a successful business and positively create purpose and impact. She said a recent staff survey showed that more than four-fifths (80%) of its staff say they like working for a company with a purpose, adding that happy staff mean higher retention rates and happy customers. 'We are a better business because we have followed many of the principles of the B Corp framework, and also through thinking about how we operate in all the different aspects we do to create positive impact in our business,' Turner told me.
Yahoo
29 minutes ago
- Yahoo
Vireo Growth Inc (VREOF) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic Expansions
Pro Forma Revenue: $90.7 million. Adjusted EBITDA: $23.2 million, with a margin of approximately 25%. Second Quarter GAAP Revenue: $48.1 million, a 91.4% increase year over year. Gross Margin: 51.6%, a reduction of 260 basis points compared to the prior year quarter. SG&A Expenses: $12.2 million, 25.4% of sales, an improvement of 480 basis points compared to Q2 last year. Adjusted Operating Income: $11.3 million, 23.5% of sales. Cash on Hand: $106.2 million at the end of Q2. Total Current Assets: $186.2 million, excluding New York assets held for sale and income taxes receivable. Total Current Liabilities: $51.8 million, excluding New York liabilities held for sale and refinanced debt. Corporate SG&A Costs: $1.8 million, a reduction of approximately 40% from the prior year quarter. Shares Outstanding: 158,617,377 shares on the Treasury method basis. Warning! GuruFocus has detected 9 Warning Signs with VREOF. Release Date: August 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Vireo Growth Inc (VREOF) reported a significant increase in GAAP revenue, up 91.4% year over year, driven by contributions from recent merger transactions. The company successfully closed three merger transactions, expanding its operational portfolio to six states and improving profitability and cash generation. Vireo Growth Inc (VREOF) completed a $153 million refinancing event, reducing annual interest expenses by approximately $10 million and increasing cash on hand to over $100 million. The company achieved an adjusted EBITDA margin of approximately 25%, with adjusted EBITDA of $23.2 million. SG&A expenses, excluding severance, improved by 480 basis points compared to the previous year, indicating better cost management. Negative Points GAAP gross margin was negatively impacted by termination fees related to a prior agreement, resulting in a reduction of 260 basis points compared to the prior year quarter. The company's performance in Minnesota was softer, affecting overall gross margin. Vireo Growth Inc (VREOF) faces uncertainty regarding the timing of adult-use cannabis sales in Minnesota, which could impact future revenue. The company is still awaiting regulatory approval for the divestment of New York assets, which could delay strategic plans. Price deflation and competition from hemp in markets like Nevada and Missouri pose challenges to maintaining market share and profitability. Q & A Highlights Q: Can you discuss the impact of the licensing agreement with Curio on your New York assets and distribution network? A: John Mazarakis, CEO & Co-Executive Chairman: The partnership with Curio does not affect the divestiture of our New York assets. Curio is a leading brand in the nutraceutical space, and we see no cannibalization with our current SKUs. We are optimistic about this relationship. Q: With the recent refinancing, what are your capital management priorities, and are there any M&A opportunities on the horizon? A: John Mazarakis, CEO & Co-Executive Chairman: We are engaging in M&A discussions, focusing on both distressed and mature spaces. While we are hopeful for M&A in the next 12 to 24 months, our primary focus remains on organic growth and achieving positive free cash flow at the unit level. Q: Can you provide an update on the Arches platform and its potential impact on growth? A: John Mazarakis, CEO & Co-Executive Chairman: We are working on deploying the Arches delivery platform. Delivery is available in all states where it is permitted, and we continue to invest in this service as we believe in its potential. Q: What preparations are being made for recreational cannabis sales in Minnesota, and how do you foresee the rollout? A: John Mazarakis, CEO & Co-Executive Chairman: We anticipate a shortage of supply in Minnesota, with initial supply coming from us and GTI. We are working with the state to ensure readiness and expect to begin adult-use sales in the second half of this year. Our retail footprint remains limited to eight locations. Q: Can you clarify the situation with your New York assets and potential partnerships there? A: John Mazarakis, CEO & Co-Executive Chairman: We are committed to a buyer for our New York assets, pending regulatory approval. Our partners have a wide network, and we aim to become the largest supplier of indoor flower in New York, leveraging this partnership. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
29 minutes ago
- Yahoo
Kamada Ltd (KMDA) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Increased ...
Total Revenue (First Half 2025): $88.8 million, up 11% year over year. Total Revenue (Q2 2025): $44.8 million, up 5% year over year. Adjusted EBITDA (First Half 2025): $22.5 million, up 35% year over year, representing a 25% margin. Adjusted EBITDA (Q2 2025): $10.9 million, up 20% year over year. Gross Profit (Q2 2025): $18.9 million with a 42% margin. Gross Profit (First Half 2025): $39.7 million with a 45% margin. Net Income (Q2 2025): $7.4 million or $0.13 per diluted share. Net Income (First Half 2025): $11.3 million or $0.19 per diluted share. Operating Expenses (Q2 2025): $11.9 million. Cash Provided by Operating Activities (Q2 2025): $8 million. Cash Balance (End of First Half 2025): $66 million. Annual Revenue Guidance 2025: $178 million to $182 million. Adjusted EBITDA Guidance 2025: Increased to $40 million to $44 million. Warning! GuruFocus has detected 4 Warning Sign with KMDA. Release Date: August 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Kamada Ltd (NASDAQ:KMDA) reported strong financial results for the first half of 2025, with total revenues of $88.8 million, representing an 11% year-over-year increase. Adjusted EBITDA for the first half of 2025 was $22.5 million, up 35% year-over-year, indicating improved profitability. The company increased its adjusted EBITDA guidance for 2025 to between $40 million and $44 million, reflecting confidence in continued profitable growth. Kamada Ltd (NASDAQ:KMDA) is advancing its PIVOTAL phase 3 inhaled clinical program, which could lead to significant future growth opportunities. The company successfully launched its first biosimilar product in Israel and plans to launch two additional biosimilars later this year, contributing to future revenue growth. Negative Points Gross profit margins decreased in the second quarter of 2025 compared to the same period in 2024, due to changes in product and territory sales mix. Operating expenses, although managed well, still represent a significant portion of revenues, which could impact future profitability if not controlled. The company's net income, while improved, is still subject to fluctuations due to changes in financial and tax expenses. The competitive landscape for Kamada Ltd (NASDAQ:KMDA)'s inhaled AAT program is evolving, with other companies developing alternative technologies that could impact market share. The company's cash position, although strong, has declined over the last couple of quarters, which may limit the scale of future business development and M&A activities. Q & A Highlights Q: Can you provide insights into the dynamics behind KEDRAB and CYTOGAM, which have been growth drivers in the past? Are they performing as expected? A: Amir London, CEO: KEDRAB and CYTOGAM are performing according to expectations. KEDRAB is supplied based on inventory management, and CYTOGAM is progressing as planned. Growth is anticipated once additional clinical data is available. The diversity of our portfolio, including products like GLASSIA and VARIZIG, supports our continued growth. Q: With a solid cash position, is it sufficient for impactful business development? How do you balance internal investments and external business development? A: Amir London, CEO: We plan to use existing cash and have additional funding sources if needed. We are focused on commercial stage assets, particularly in plasma-derived products and specialty pharma. We are actively screening multiple targets and expect meaningful impact on our 2026 performance. Q: Can you describe the competitive landscape for the inhaled AAT program? Are there developments that might change the market opportunity? A: Amir London, CEO: Our inhaled program is the most advanced in terms of efficacy studies. The market is growing, and we expect it to be a $2 billion market by the time we have study results. Our technology offers better ease of use and quality of life, positioning us as a strong competitor. Q: Was there any one-time sales impact in the distribution revenue segment this quarter? How should we view this channel going forward? A: Amir London, CEO: There were no one-time sales. The launch of the biosimilar product builds on our existing infrastructure, and we expect continued growth. This will help improve our margins over the next few years. Q: What was responsible for the tax credit in the June quarter, and what do you expect the tax rate to be in the future? A: Chaime Orlev, CFO: Fluctuations in currency exchange affected our tax results. We anticipate utilizing all tax loss carryforwards by the end of 2025, moving into tax payments. The effective tax rate is expected to be between 20% and 25% in 2026 and beyond. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
